Literature DB >> 32857840

Advancing Assessment, Analysis, and Reporting of Safety and Tolerability in Cancer Trials.

Paul G Kluetz1,2, Bellinda L King-Kallimanis1, Daniel Suzman1, Elaine Chang1, Michael M Brave1, Chana Weinstock1, Vishal Bhatnagar1, Julia A Beaver1,2, Meredith K Chuk2.   

Abstract

Entities:  

Mesh：

Year:  2021        PMID： 32857840      PMCID： PMC8096361          DOI： 10.1093/jnci/djaa135

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  5 in total

1.  Focusing on Core Patient-Reported Outcomes in Cancer Clinical Trials: Symptomatic Adverse Events, Physical Function, and Disease-Related Symptoms.

Authors:  Paul G Kluetz; Ashley Slagle; Elektra J Papadopoulos; Laura Lee Johnson; Martha Donoghue; Virginia E Kwitkowski; Wen-Hung Chen; Rajeshwari Sridhara; Ann T Farrell; Patricia Keegan; Geoffrey Kim; Richard Pazdur
Journal:  Clin Cancer Res       Date:  2016-01-12       Impact factor: 12.531

Review 2.  Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards.

Authors:  Andrew Bottomley; Madeline Pe; Jeff Sloan; Ethan Basch; Franck Bonnetain; Melanie Calvert; Alicyn Campbell; Charles Cleeland; Kim Cocks; Laurence Collette; Amylou C Dueck; Nancy Devlin; Hans-Henning Flechtner; Carolyn Gotay; Eva Greimel; Ingolf Griebsch; Mogens Groenvold; Jean-Francois Hamel; Madeleine King; Paul G Kluetz; Michael Koller; Daniel C Malone; Francesca Martinelli; Sandra A Mitchell; Carol M Moinpour; Jammbe Musoro; Daniel O'Connor; Kathy Oliver; Elisabeth Piault-Louis; Martine Piccart; Francisco L Pimentel; Chantal Quinten; Jaap C Reijneveld; Christoph Schürmann; Ashley Wilder Smith; Katherine M Soltys; Martin J B Taphoorn; Galina Velikova; Corneel Coens
Journal:  Lancet Oncol       Date:  2016-10-18       Impact factor: 41.316

3.  Pazopanib versus sunitinib in metastatic renal-cell carcinoma.

Authors:  Robert J Motzer; Thomas E Hutson; David Cella; James Reeves; Robert Hawkins; Jun Guo; Paul Nathan; Michael Staehler; Paul de Souza; Jaime R Merchan; Ekaterini Boleti; Kate Fife; Jie Jin; Robert Jones; Hirotsugu Uemura; Ugo De Giorgi; Ulrika Harmenberg; Jinwan Wang; Cora N Sternberg; Keith Deen; Lauren McCann; Michelle D Hackshaw; Rocco Crescenzo; Lini N Pandite; Toni K Choueiri
Journal:  N Engl J Med       Date:  2013-08-22       Impact factor: 91.245

4.  Inferences About Drug Safety in Phase III Trials in Oncology: Examples From Advanced Prostate Cancer.

Authors:  Joshua Z Drago; Mithat Gönen; Gita Thanarajasingam; Chana A Sacks; Michael J Morris; Philip W Kantoff; Konrad H Stopsack
Journal:  J Natl Cancer Inst       Date:  2021-05-04       Impact factor: 13.506

Review 5.  An FDA Review of Drug Development in Nonmetastatic Castration-resistant Prostate Cancer.

Authors:  Michael Brave; Chana Weinstock; Jamie R Brewer; Dow-Chung Chi; Daniel L Suzman; Joyce Cheng; Lijun Zhang; Rajeshwari Sridhara; Amna Ibrahim; Paul G Kluetz; Richard Pazdur; Julia A Beaver
Journal:  Clin Cancer Res       Date:  2020-04-13       Impact factor: 12.531
  5 in total
  2 in total

Review 1.  Reaching beyond maximum grade: progress and future directions for modernising the assessment and reporting of adverse events in haematological malignancies.

Authors:  Gita Thanarajasingam; Lori M Minasian; Vishal Bhatnagar; Franco Cavalli; R Angelo De Claro; Amylou C Dueck; Tarec C El-Galaly; Neil Everest; Jan Geissler; Christian Gisselbrecht; Nicole Gormley; John Gribben; Mary Horowitz; S Percy Ivy; Caron A Jacobson; Armand Keating; Paul G Kluetz; Yok Lam Kwong; Richard F Little; Matthew J Matasar; Maria-Victoria Mateos; Kristen McCullough; Robert S Miller; Mohamad Mohty; Philippe Moreau; Lindsay M Morton; Sumimasa Nagai; Abhilasha Nair; Loretta Nastoupil; Kaye Robertson; Surbhi Sidana; Karin E Smedby; Pieter Sonneveld; Kyriaki Tzogani; Flora E van Leeuwen; Galina Velikova; Diego Villa; John R Wingard; John F Seymour; Thomas M Habermann
Journal:  Lancet Haematol       Date:  2022-05       Impact factor: 30.153

Review 2.  Understanding Treatment Tolerability in Older Adults With Cancer.

Authors:  Marie A Flannery; Eva Culakova; Beverly E Canin; Luke Peppone; Erika Ramsdale; Supriya G Mohile
Journal:  J Clin Oncol       Date:  2021-05-27       Impact factor: 44.544
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.